Sanofi diabetes franchise in focus, shares trade steadily in Paris

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 21:12.

Sanofi S.A. (FR0000120578) remains closely watched for its diabetes and obesity portfolio. The French drugmaker trades on Euronext Paris, where large-cap peers like Novo Nordisk and Eli Lilly also anchor investor attention according to recent market commentary from Reuters.

Analysts track diabetes and obesity pipeline

Sanofi has been repositioning its portfolio toward immunology and specialty care while keeping a strategic focus on diabetes, where it historically derived substantial revenue from products such as Lantus and Toujeo. Recent analyst notes highlight that investors are increasingly comparing Sanofi's next-generation GLP-1 candidates with established obesity treatments from Novo Nordisk and Eli Lilly, a dynamic that shapes valuation discussions in the sector per coverage compiled by MarketScreener.

Broker research summarized on MarketScreener shows a mix of Buy and Hold ratings, with several houses citing the potential of Sanofi's pipeline and cost adjustments to offset patent expiries in mature diabetes products. An overview of consensus metrics on Sanofi's shares can be found in the aggregated analyst section on MarketScreener, which tracks target prices and rating changes across major European and U.S. banks.

Consensus and valuation backdrop for Sanofi shares

Consensus data compiled by MarketScreener indicates that a majority of analysts covering Sanofi maintain positive to neutral views, with their models sensitive to upcoming clinical milestones and potential regulatory submissions in metabolic and autoimmune diseases. Investors frequently benchmark Sanofi's valuation against global big pharma peers such as Pfizer, Novartis and AstraZeneca, considering factors like pipeline breadth, patent cliffs and capital allocation. Further market commentary from Reuters has emphasized how shifting expectations on obesity and diabetes treatments influence price-to-earnings multiples across the sector.

How Sanofi makes its money

Sanofi generates revenue from prescription pharmaceuticals, vaccines and consumer health products, with key franchises in diabetes, cardiovascular, oncology, immunology and rare diseases. Its vaccines business operates through Sanofi Pasteur, while the consumer health unit markets over-the-counter brands in pain relief, allergy and digestive care.

Where the stock trades today

Sanofi shares trade on Euronext Paris under the ticker SAN, with additional listings in the form of American Depositary Receipts (ADRs) on NASDAQ, giving international investors direct access to the French pharmaceutical group.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.